Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs - 2New method spots signs of Earth's primordial life in ancient rocks
- 3Figure out How to Recognize the Right Areas for 5G Pinnacles\
- 4Very good quality Greens All over The Planet
- 5Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- 7 Heavenly Espressos, One Do You Like?
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
- My Pioneering Excursion: Building a Startup
- Party Urban areas of the World
- Best Pizza Beating: What's Your #1?
- Knesset sets special panel to fast-track Karhi’s communications reform
- Step by step instructions to Choose the Right Auto Crash Legal counselor for Your Case
